Company intelligence / Profile preview

Vivosang, Inc.

Ownership: Private
Development stage: Preclinical

Overview

Vivosang, Inc. is developing a hemoglobin-based oxygen carrier made from human hemoglobin linked to polyethylene glycol. This product aims to serve as a temporary substitute for red blood cells in situations where transfusion is not possible or practical. The company’s chief science officer has stated that their approach seeks to address previous safety concerns with HBOCs by improving the molecular design and delivery method[2].

Therapeutic areas: OtherHematology
Modalities: Hemoglobin-based oxygen carriers (HBOCs)Polymer-conjugated proteins (PEGylated hemoglobin)
Industry: Biotech

Drug pipeline

1 asset

HBOC

Pre-clinical

Indications: Hemorrhagic shock, Blood loss, Anemia

Partnerships

U.S. military funding ($46 million grant reported)[2]No other major pharmaceutical partnerships identified.

Beyond the preview

Go deeper on Vivosang, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vivosang, Inc..

Explore the full profile